RKTO

Rocket One is a clinical-stage biopharma that has never booked a dollar of revenue (FY2021–FY2025 revenue all blank) and, by its own admission, expects 'to continue to operate at a net loss for at least the next several years.' The FY2025 net loss widened to $12.5M from $8.2M (-52.3% YoY), driven by an 83% jump in R&D to $5.95M (chiefly $3.6M on lead asset HT-001) and a 29% rise in G&A to $6.4M — the latter inflated by an 800,000-share grant to the CEO valued at $968K. Losses are accelerating, not narrowing, and the accumulated deficit now stands at -$72.9M.

The decisive problem is the runway. Cash is $6.25M against operating cash burn of -$9.8M per year — roughly eight months of liquidity. The filing is explicit that the company 'will need to raise substantial additional capital' and warns that 'the capital markets have been unpredictable for unprofitable companies such as ours' and that any raise may be 'dilutive to you.' Shares already grew 23.4% YoY, so dilution is not a tail risk — it is the base case, and it will come at a $0.89 stock price near penny-stock territory. ROE of -202.7% quantifies how fast equity is being consumed.